FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Adverse experiences and chronic stress are well-known risk factors for the development of major depression, and an impaired stress response regulation is frequently observed in acute depression. Impaired glucocorticoid receptor (GR) signalling plays an important role in these alterations, and a restoration of GR signalling appears to be a prerequisite of successful antidepressant treatment. Variants in genes of the stress response regulation contribute to the vulnerability to depression in traumatized subjects. Consistent findings point to an important role of FKBP5, the gene expressing FK506-binding protein 51 (FKBP51), which is a strong inhibitor of the GR, and thus, an important regulator of the stress response. We investigated the role of FKBP5 and FKB51 expression with respect to stress response regulation and antidepressant treatment outcome in depressed patients. This study included 297 inpatients, who participated in the Munich Antidepressant Response Signature (MARS) project and were treated for acute depression. In this open-label study, patients received antidepressant treatment according to the attending doctor’s choice. In addition to the FKBP5 genotype, changes in blood FKBP51 expression during antidepressant treatment were analyzed using RT-PCR and ZeptoMARKTM reverse phase protein microarray (RPPM). Stress response regulation was evaluated in a subgroup of patients using the combined dexamethasone (dex)/corticotropin releasing hormone (CRH) test. As expected, increased FKBP51 expression was associated with an impaired stress response regulation at baseline and after six weeks was accompanied by an elevated cortisol response to the combined dex/CRH test. Further, we demonstrated an active involvement of FKBP51 in antidepressant treatment outcome. While patients responding to antidepressant treatment had a pronounced reduction of FKBP5 gene and FKBP51 protein expression, increasing expression levels were observed in nonresponders. This effect was moderated by the genotype of the FKBP5 single nucleotide polymorphism (SNP) rs1360780, with carriers of the minor allele showing the most pronounced association. Our findings demonstrate that FKBP5 and, specifically, its expression product FKBP51 are important modulators of antidepressant treatment outcome, pointing to a new, promising target for future antidepressant drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, an increased FKBP5 mRNA expression was associated with HPA axis dysfunction and worse response to antidepressants in patients suffering from MDD [121].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“FKBP5 RNA quantification was calculated against the activity of four housekeeping genes (beta-glucuronidase, hypoxanthine–guanine phosphoribosyltransferase 1, phospholipase A2, and TATA-box binding protein) using the delta cycle threshold (CT) method [43] for each housekeeping gene.”
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621 · cited 1×
“The glucocorticoid receptor (GR) complex plays a critical role in HPA axis regulation [9,15] as impaired GR signalling results in an attenuated negative-feedback inhibition of the HPA axis, finally leading to chronically elevated glucocorticoid levels.”
Self-citationHammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181 · cited 2×
“In fact, acute depression is frequently accompanied by a disturbed stress response regulation, which is indicated, for instance, by elevated endocrine responses to pharmacological challenges of the hypothalamus–pituitary–adrenocortical (HPA) axis, the major stress regulation system [9].”
Self-citationKendler, K. S., Prescott, C. A., Myers, J., & Neale, M. C. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.929 · Cited by 1,868 · cited 2×
“As depression is a multifactorial disorder, genetic and environmental factors also contribute substantially to depression risk and outcome development [4].”
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
Cited by
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Recently, an increased FKBP5 mRNA expression was associated with HPA axis dysfunction and worse response to antide-pressants in patients suffering from MDD [121].”
BackgroundPharmacogenomics: A road ahead for precision medicine in psychiatry
Pardiñas, A. F., Owen, M. J., & Walters, J. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.011 · Cited by 91
Fu, C., Chen, Z., Chen, M., Chen, G., Huang, Q., Yang, X., Yin, H., Chen, L., Zhang, W., Lin, H., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00231-6 · Cited by 66
Biomarkers in Child and Adolescent Depression
Zwolińska, W., Dmitrzak‐Węglarz, M., & Słopień, A. (2021) · Child Psychiatry & Human Development · doi:10.1007/s10578-021-01246-y · Cited by 77
Malekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., Azarpira, N., & Ebrahimi, N. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1182345 · Cited by 86
Inhibition of FKBP51 induces stress resilience and alters hippocampal neurogenesis
Codagnone, M. G., Kara, N. Z., Ratsika, A., Levone, B. R., van de Wouw, M., Tan, L. A., Cunningham, J. I., Sánchez, C., Cryan, J. F., & O’Leary, O. F. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01755-9 · Cited by 49
Nohesara, S., Abdolmaleky, H. M., Zhou, J., & Thiagalingam, S. (2023) · Genes · doi:10.3390/genes14122217 · Cited by 26
“…bacteria exhibited significant alterations, this was associated with DNA hypomethylation of the FKBP5 gene, which together with NF-κ B mediates inflammation and stress responses, and its increased expression is associated with impaired stress responses and unresponsiveness to antidepressants [72].”
BackgroundPeña, E., Caixàs, A., Arenas, C., Rigla, M., Crivillés, S., Cardoner, N., & Rosa, A. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.12.002 · Cited by 22
Suh, J. S., Fiori, L. M., Ali, M., Harkness, K. L., Ramonas, M., Minuzzi, L., Hassel, S., Strother, S. C., Zamyadi, M., Arnott, S. R., et al. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105348 · Cited by 22
“…is a chaperone to GR, and the two have been implicated in multiple studies with respect to MDD susceptibility and risk (Roy et al., 2017; Rao et al., 2016; Piechaczek et al., 2019), antidepressant response (Ising et al., 2019; Binder et al., 2004) and childhood maltreatment (Bockmühl et al., 2015).”
BackgroundJones, C., & Nemeroff, C. B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_27 · Cited by 28
Chalermwongkul, C., Khamphukdee, C., Daodee, S., Monthakantirat, O., Boonyarat, C., Chotritthirong, Y., Maneenet, J., Awale, S., Kijjoa, A., & Chulikhit, Y. (2023) · Nutrients · doi:10.3390/nu15224742 · Cited by 26
“However further investigations are still needed to deepen our understanding and knowledge of the safety profile, contraindications, interactions with other drugs, and fine molecular mechanisms underlying the beneficial effects of OIS extract.”
BackgroundBlood transcriptional response to treatment-resistant depression during electroconvulsive therapy
Israel‐Elgali, I., Hertzberg, L., Shapira, G., Segev, A., Krieger, I., Nitzan, U., Bloch, Y., Pillar, N., Mayer, O., Weizman, A., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.039 · Cited by 20
Tricyclic antidepressants target FKBP51 SUMOylation to restore glucocorticoid receptor activity
Budziñski, M. L., Sokn, C., Gobbini, R., Ugo, B., Antunica-Noguerol, M., Senin, S., Bajaj, T., Gassen, N. C., Rein, T., Schmidt, M. V., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01491-0 · Cited by 17
“With the aim of finding inhibitors of FKBP51 SUMOylation, and based on the importance of GR/FKBP51 pathway as target of antidepressant activity [11, 17, 29, 30, 37, 46, 47], we investigated if they could inhibit FKBP51 SUMOylation and therefore improve GR activity.”
BackgroundChapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Zhang, Y., Yue, W., & Li, J. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05717-z · Cited by 22
“Successful antidepressant treatment necessitates normal GR function [29, 38, 39].”
BackgroundLi, H., Meng, G., Lu, B., Wang, W., Fu, Y., Jiao, L., & Wu, W. (2024) · Phytotherapy Research · doi:10.1002/ptr.8075 · Cited by 16
“pathogenesis of depression is notably linked to the hyperactivity of the hypothalamic – pituitary – adrenal (HPA) axis (Adams et al., 2021; Ising et al., 2019; O'Keane et al., 2012).”
Pisanu, C., Severino, G., Toma, I. D., Dierssen, M., Fusar‐Poli, P., Gennarelli, M., Lió, P., Maffioletti, E., Maron, E., Mehta, D., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.12.005 · Cited by 15
Stassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Herzig, D., Schneeberger, A. R., & Seifritz, E. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01169-0 · Cited by 16
Schultchen, D., Küchler, A., Schillings, C., Weineck, F., Karabatsiakis, A., Ebert, D. D., Baumeister, H., & Pollatos, O. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032775 · Cited by 19
Therapeutic Potential of the Purinergic System in Major Depressive Disorder Associated with COVID-19
Simões, J. L. B., Galvan, A. C. L., da Silva, E. L. M., Ignácio, Z. M., & Bagatini, M. D. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01215-6 · Cited by 13
Corticosterone-induced Hippocampal 5-HT Responses were Muted in Depressive-like State
Sun, X., Zu, Y., Li, X., Zhao, S., Sun, X., Li, L., Zhang, X., Wang, W., Liang, Y., Wang, W., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00334 · Cited by 15
Liu, Y., Lian, J., Fu, Y., Wang, S., Liu, Y., Zhang, R., & Han, H. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100762 · Cited by 13
“Antidepressant response dynamically modulates FKBP5 mRNA and FKBP51 protein levels: responders exhibit decreased peripheral expression after 6 weeks, whereas non-responders maintain elevated levels (Ising et al., 2019).”
Multi-omics in exploring the pathophysiology of diabetic retinopathy
Li, X., Dong, X., Zhang, W., Shi, Z., Liu, Z., Sa, Y., Li, L., Ni, N., & Mei, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1500474 · Cited by 17
Nøhr, A. K., Lindow, M., Forsingdal, A., Demharter, S., Nielsen, T. T., Buller, R., Moltke, I., Vitezic, M., & Albrechtsen, A. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01002-9 · Cited by 14
Kerr, P., LUPIEN, S. J., & Juster, R. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104634 · Cited by 12
Zhang, C., Cui, X., Feng, L., Han, Z., Peng, D., Fu, W., & Xing, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-71 · Cited by 10
“Previous research has suggested that FKBP-5 is widely expressed in kidney, skeletal muscle, liver, placenta, heart, peripheral lymphocyte, small intestine, ovary, testis, thymus, and lymph node (36-39).”
BackgroundGallo, M. T., Brivio, P., Dolci, B., Fumagalli, F., & Calabrese, F. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.08.016 · Cited by 12
“…we found that Fkbp5 and Gadd45 β mRNA levels were selectively increased in male rats exposed to perinatal FLX and this is extremely interesting since these genes have been previously associated with altered stress response and antidepressant treatments (Ising et al., 2019; Shen et al., 2022).”
Transcriptome sequencing reveals a lncRNA–mRNA interaction network in extramammary Paget’s disease
Zheng, D., Shen, Y., Wei, Z., Wan, X., Xie, M., Yao, H., & Wang, Z. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01135-2 · Cited by 8
“It has been identified to be associated with mental disorders, inflammation and cardiovascular diseases [44, 45].”
BackgroundBiomarker-Guided Tailored Therapy in Major Depression
Perna, G., Spiti, A., Torti, T., Daccò, S., & Caldirola, D. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_19 · Cited by 11
SUMO conjugation as regulator of the glucocorticoid receptor-FKBP51 cellular response to stress
Liberman, A. C., Budziñski, M. L., Sokn, C., Gobbini, R. P., Ugo, M. B., & ARZT, E. S. (2019) · Steroids · doi:10.1016/j.steroids.2019.108520 · Cited by 8
Endocannabinergic modulation of central serotonergic activity in healthy human volunteers
Emons, B., Arning, L., Makulla, V.-E., Suchy, M.-T., Tsikas, D., Lücke, T., Epplen, J. T., Juckel, G., & Roser, P. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-023-00437-2 · Cited by 6
Labaka, A., Gómez-Lázaro, E., Goñi‐Balentziaga, O., Pérez-Tejada, J., Vegas, Ó., & Garmendia, L. (2021) · Stress · doi:10.1080/10253890.2021.1895111 · Cited by 8
Fuller, K. C., Gravlee, C. C., McCarty, C., Mitchell, M. M., & Mulligan, C. J. (2021) · American Journal of Physical Anthropology · doi:10.1002/ajpa.24362 · Cited by 6
Hertzberg, L., Zohar, A. H., & Yitzhaky, A. (2021) · Life · doi:10.3390/life11030190 · Cited by 5
“For example, it was found to be positively correlated with symptoms of anxiety and depression in women [49], was correlated with the response of individuals with PTSD to cognitive behavioral therapy [50] and with the response of individuals with depression to antidepressants [51].”
Exploring the Link Between the Gut Microbiota and Epigenetic Factors in Anorexia Nervosa
Korten, N. M., Thelen, A. C., Voelz, C., Beyer, C., Seitz, J., Trinh, S., & Blischke, L. (2025) · Brain and Behavior · doi:10.1002/brb3.70733 · Cited by 5
Poletti, F., González-Fernández, R., García, M.-D.-P., Rotoli, D., Ávila, J., Mobasheri, A., & Martín-Vasallo, P. (2021) · Cells · doi:10.3390/cells10092196 · Cited by 4
Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes?
Zheng, N., Niu, M., Zang, Y., Zhuang, H., Jia, F., Bao, S., & Liu, S. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230907093349 · Cited by 5
Teng, T., Wu, Q., Yin, B., Zhang, J., Li, X., Zhang, L., Zhou, X., & Xie, P. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01412-5 · Cited by 4
Reelin, the HPA Axis, and Chronic Stress: Implications for the Neurobiology of Depression
Thom, S. A., Halvorson, C. S., Reive, B. S., Sánchez-Lafuente, C. L., Kalynchuk, L. E., & Caruncho, H. J. (2026) · Chronic Stress · doi:10.1177/24705470261427267 · Cited by 4
“128 FKBP5 regulates GR sensitivity by reducing their binding af fi nity for cortisol and at high levels can impair the negative feedback loop regulating the HPA axis, making it more prone to hyperactivity.”
King, A. C., & Zenker, A. K. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1187302 · Cited by 4
“In a previous study, patients who responded to anti-depressant treatment had a significant reduction of fkbp5 gene and associated fkbp51 protein expression, whereas an increasing expression level of fkbp5 was observed in non-responders (Ising et al., 2019).”
BackgroundHu, Y., He, Z., Yuan, Y., Meng, Y., Cao, Y., Zeng, Z., Du, F., & Koole, S. L. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02808-4 · Cited by 4
“However, previous Gene × Environment (G x E) studies focusing on single genes, particularly those in the serotonin and HPA axis, have often yielded small, unstable effects, making replication challenging [21].”
Dillenburger, B., Häberlein, H., & Kolb, C. (2020) · Nervenheilkunde · doi:10.1055/a-1202-2989 · Cited by 4
“verdeutlicht: In einer Patientenkohorte sank die FKBP5-Expression mit antidepressiver Therapie bei Respondern [12].”
BackgroundInfluentialSUMO regulation of FKBP51 activity and the stress response
Gobbini, R. P., Velardo, V. G., Sokn, C., Liberman, A. C., & ARZT, E. S. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30411 · Cited by 3
Hormonal contraceptives modulate resilience to psychiatric and neurodegenerative disease
Schuh, K. M., Conrad, L. M., & Tronson, N. C. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105823 · Cited by 3
Fang, T., Liu, M., Tian, X.-Y., Lu, G.-Y., Li, F. Y., Zhang, X., Liu, F., Hao, W., Wu, N., Li, H., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1147060 · Cited by 3
Molecular Psychiatry: Trends and Study Examples
Rein, T., & Fries, G. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020459 · Cited by 2
Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders
Lam, Y. W. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00142-0 · Cited by 1
Jalalian, M., Pourasghar, M., Majd, A., Ghalehnoei, H., & Kianmehr, Z. (2024) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs-153409 · Cited by 1
Potential risk factors of susceptibility to recurrent depression
Wang, S., Guo, L., & Wang, C. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111374 · Cited by 1
“A single-nucleotide polymorphism in FKBP5 , a gene coding for a synergistic partner molecule of HSP90, was significantly associated with the response to rapid antidepressants and recurrence of depression (Binder et al., 2004; Ising et al., 2019); 2.”
Li, C., Huang, J., Ge, H., Si, L., Wu, L., Xie, Y., Xiao, L., & Wang, G. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag018 · Cited by 1
Circulating FK506 binding protein 51 mRNA expression in patients with pituitary adenomas
Yang, Y., Babayan, L., Mirzakhanian, A., Sisliyan, N., Zhang, D., Hurtado, C., Zahid, A., Bergsneider, M., Kim, W. B., Wang, M. B., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2022.e12678 · Cited by 2
Differentially expressed heterogeneous overdispersion genes testing for count data
Yuan, Y., Xu, Q., Wani, A. H., Dahrendorff, J., Wang, C. C. Q., Shen, A., Donglasan, J., Burgan, S. C., Graham, Z., Uddin, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300565 · Cited by 1
“In many studies using different cell types, the dysregulation phenomenon of FKPB5 is found in many stress-related psychopathologies via investigating single nucleotide polymorphisms [42, 43], gene expression [44], and DNA methylation profiles [45].”
Matosin, N., Arloth, J., Czamara, D., Edmond, K. Z., Maitra, M., Fröhlich, A. S., Martinelli, S., Kaul, D., Bartlett, R., Curry, A. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.27.428487 · Cited by 1
“It is important to note that there may be effects of medication, especially antidepressants, in cases, given that reductions in blood FKBP5 mRNA and protein expression during antidepressant treatment has been reported(Ising et al., 2019).”
BackgroundIglesias, L. P., Coelho, A. A., da Silva, N. R., Müller, H. K., Moreira, F. A., Wegener, G., & Joca, S. R. L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.14.507883 · Cited by 1
“seems to participate in antidepressants’ effect (79, 80).”
BackgroundChalermwongkul, C., Khamphukdee, C., Daodee, S., Monthakantirat, O., Boonyarat, C., Chotritthirong, Y., Maneenet, J., Awale, S., Kijjoa, A., & Chulikhit, Y. (2023) · Preprints.org · doi:10.20944/preprints202308.1808.v1
Bordes, J., Stont, L., Bajaj, T., Chang, S., Ebert, T., Miranda, L., Schlegel, P., Reinhardt, M., Pöhlmann, M., Mecdad, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693477 · Cited by 1
“Human genetic studies have implicated polymorphisms in the FKBP5 gene in susceptibility to MDD 15 – 17 , particularly in individuals exposed to severe stress 18 – 20 .”
FKBP5 gene expression as a biomarker for treatment outcome in depression
Ising, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00026-x
Self-citationEmotionale und depressive Störungen bei Kindern und Jugendlichen
Lincke, L., & Kölch, M. G. (2021) · Kinder- und Jugendmedizin · doi:10.1055/a-1404-6527
“[13] Ising M, Maccarrone G, Brückl T et al.”
BackgroundProgress in Biomarkers to Improve Treatment Outcomes in Major Depressive Disorder
Vaccarino, S. R., Ceniti, A. K., Rotzinger, S., & Kennedy, S. H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.024
Mikoteit, T., Galli, S., Stäuble, C. K., Zeising, M., Steiger, A., Binder, E. B., Hatzinger, M., & zu Schwabedissen, H. E. M. (2025) · Pharmacopsychiatry · doi:10.1055/s-0045-1807307
Metadata
- Authors
- Ising, M., Maccarrone, G., Brückl, T., Scheuer, S., Hennings, J., Holsboer, F., Turck, C. W., Uhr, M., & Lucae, S.
- Affiliations
- Max Planck Institute of Psychiatry (DE)
- kbo-Isar-Amper Clinical Center Munich East, 85540 Munich, Germany
- HolsboerMaschmeyer NeuroChemie (Germany) (DE)
- Corresponding author
- Ising, Marcus
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-23
- Volume
- 20
- Issue
- 3
- Pages
- 485
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6387218
- OpenAlex
- W2914861780
- Cited by
- 60
- References
- 43
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 5 · 2021: 18 · 2020: 5 · 2019: 2
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung (01ES0811)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- FKBP5, FKBP51, antidepressant treatment outcome, depression, stress response regulation, cortisol response, dexamethasone/corticotropin-releasing hormone test, rs1360780, gene expression, acute depression
- MeSH terms
- Tacrolimus Binding Protein 5, Adult, Alleles, Antidepressive Agents, Depression, Female, Genotype, Humans, Hypothalamo-Hypophyseal System, Longitudinal Studies, Male, Middle Aged, Pituitary-Adrenal System, Prognosis, Time Factors, Biomarkers, Gene Expression, Treatment Outcome, Tacrolimus Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.